BTIG lowered the firm’s price target on Xtant Medical (XTNT) to $2 from $3 and keeps a Buy rating on the shares. The company’s loss per share was worse than expected as gross margins were impacted by inventory charges related to Surgalign and product optimization in OrthoBiologics, the analyst tells investors in a research note. The management believes however that they are setting achievable guidance for FY25 coupled with reduced operating expenses in order to manage cash and simplify the business profile, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue